DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
- PMID: 35296003
- PMCID: PMC8918526
- DOI: 10.3389/fonc.2022.849376
DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
Abstract
DNMT3A mutations play a prominent role in clonal hematopoiesis and myeloid neoplasms with arginine (R)882 as a hotspot, however the clinical implications of R882 vs. non-R882 mutations in myeloid neoplasms like myelodysplastic syndrome (MDS) is unclear. By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). Next with the largest cohort of patients with DNMT3A R882 mutant MDS known to date from multiple institutions, DNMT3A R882 mutant MDS cases were shown to have more severe leukopenia, enriched SRSF2 and IDH2 mutations, increased cases with excess blasts (47% vs 22.5%, p=.004), markedly increased risk of AML transformation (25.8%, vs. 1.7%, p=.0001) and a worse progression-free survival (PFS) (median 20.3, vs. >50 months, p=.009) than non-R882 mutant MDS cases. DNMT3A R882 mutation is an independent risk factor for worse PFS, and importantly the differences in the risk of AML transformation between R882 vs. non-R882 mutant patients cannot be explained by different treatment approaches. Interestingly the higher risk of AML transformation and the worse PFS in DNMT3A R882 mutant MDS cases are mitigated by coexisting SF3B1 or SRSF2 mutations. The unique clinicopathologic features of DNMT3A R882 mutant MDS shed light on the prognostic and therapeutic implications of DNMT3A R882 mutations.
Keywords: DNMT3A; R882 mutations; acute myeloid leukemia; genetics; myelodysplastic syndromes.
Copyright © 2022 Jawad, Afkhami, Ding, Zhang, Li, Young, Xu, Cui, Zhao, Halene, Al-Kali, Viswanatha, Chen, He and Zheng.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8918526/bin/fonc-12-849376-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8918526/bin/fonc-12-849376-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8918526/bin/fonc-12-849376-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8918526/bin/fonc-12-849376-g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8918526/bin/fonc-12-849376-g005.gif)
Similar articles
-
Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.PLoS One. 2011;6(10):e26906. doi: 10.1371/journal.pone.0026906. Epub 2011 Oct 31. PLoS One. 2011. PMID: 22066015 Free PMC article.
-
DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):61-6. doi: 10.1016/j.bcmd.2014.01.004. Epub 2014 Feb 8. Blood Cells Mol Dis. 2014. PMID: 24512939
-
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.Br J Haematol. 2016 Oct;175(2):226-236. doi: 10.1111/bjh.14254. Epub 2016 Aug 1. Br J Haematol. 2016. PMID: 27476855 Free PMC article.
-
DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.Medicine (Baltimore). 2016 May;95(18):e3519. doi: 10.1097/MD.0000000000003519. Medicine (Baltimore). 2016. PMID: 27149454 Free PMC article. Review.
-
DNMT3A-R882: a mutation with many paradoxes.Ann Hematol. 2024 Jul 6. doi: 10.1007/s00277-024-05874-x. Online ahead of print. Ann Hematol. 2024. PMID: 38969930 Review.
Cited by
-
Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia.Biomed Res Int. 2024 May 21;2024:9625043. doi: 10.1155/2024/9625043. eCollection 2024. Biomed Res Int. 2024. PMID: 38807916 Free PMC article.
-
A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.Curr Oncol. 2024 Apr 23;31(5):2353-2363. doi: 10.3390/curroncol31050175. Curr Oncol. 2024. PMID: 38785456 Free PMC article. Review.
-
Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.Leukemia. 2024 Jul;38(7):1501-1510. doi: 10.1038/s41375-024-02211-z. Epub 2024 Mar 11. Leukemia. 2024. PMID: 38467769 Free PMC article.
-
Analysis of the clinical characteristics and prognosis of adult de novo acute myeloid leukemia (none APL) with PTPN11 mutations.Open Med (Wars). 2023 Nov 3;18(1):20230830. doi: 10.1515/med-2023-0830. eCollection 2023. Open Med (Wars). 2023. PMID: 38025540 Free PMC article.
-
Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.Clin Epigenetics. 2023 Sep 13;15(1):150. doi: 10.1186/s13148-023-01566-x. Clin Epigenetics. 2023. PMID: 37705055 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous